Summary

This extension study of the phase 3 PAOLA trial found that pasireotide LAR may be a viable, long-term treatment option for patients with acromegaly that is inadequately controlled with first-generation somatostatin analogues. Biochemical control of growth hormone and normalized insulin-like growth factor 1 continued through extension week 28.